Regenxbio (RGNX) FCF Margin (2014 - 2025)

Regenxbio's FCF Margin history runs 12 years deep, the most recent figure standing at 200.52% for Q4 2025.

• In Q4 2025, FCF Margin fell 5301.0% year-over-year to 200.52%; the TTM figure through Dec 2025 stood at 76.46% (up 13216.0% YoY), while the FY2025 annual figure was 80.87%, up 12592.0% from the prior year.
• FCF Margin for Q4 2025 stood at 200.52%, down from 196.24% in the prior quarter.
• The five-year high for FCF Margin was 102.54% in Q4 2021, with the low at 447.99% in Q1 2023.
• The 5-year median for FCF Margin is 198.37% (2022), against an average of 194.59%.
• The sharpest annual moves came in 2021 and 2025: FCF Margin plunged 32879 bps in 2021, then jumped 40250 bps in 2025.
• Regenxbio's FCF Margin stood at 102.54% in 2021, then plunged by 216 bps to 119.38% in 2022, then retreated by 14 bps to 136.57% in 2023, then dropped by 8 bps to 147.51% in 2024, then plunged by 36 bps to 200.52% in 2025.
• Business Quant data shows RGNX's FCF Margin at 200.52% in Q4 2025, 196.24% in Q3 2025, and 216.29% in Q2 2025.